AI Article Synopsis
- * The study involved 69 diabetic patients, dividing them into HFpEF (40) and non-HFpEF (29) groups, and used Receiver Operating Characteristics (ROC) curve analysis to evaluate FGF21, galectin-3, and copeptin.
- * FGF21 levels were significantly higher in HFpEF patients (mean 298.98 pg/mL) compared to non-HFpEF (mean 146.79 pg/mL), showing promise as a diagnostic
Article Abstract
More than half of the patients with heart failure have preserved ejection fraction (HFpEF), however evidence shows a mortality rate comparable to those with reduced ejection fraction. The aim of this study was to evaluate whether FGF21, galectin-3 and copeptin can be used as biomarkers to identify HFpEF in patients with confirmed type 2 diabetes mellitus (DM). Sixty-nine diabetic patients were enrolled and divided into two groups: patients with HFpEF ( = 40) and those without HFpEF ( = 29). The ability of the studied biomarkers to discriminate HFpEF cases from non-HFpEF subjects were evaluated by the area under the Receiver Operating Characteristics (ROC) curve and the 95% confidence interval (CI). Compared to patients without heart failure, those with HFpEF had significantly higher levels of FGF21 (mean 146.79 pg/mL vs. 298.98 pg/mL). The AUC value of FGF21 was 0.88, 95% CI: [0.80, 0.96], Se = 85% [70.2, 94.3], Sp = 79.3% [60.3, 92.0], at an optimal cut-off value of 217.40 pg/mL. There was no statistical significance associated with galectin-3 and copeptin between patient cohorts. In conclusion, galectin-3 and copeptin levels were not effective for detecting HFpEF, while FGF21 is a promising biomarker for diagnosing HFpEF in DM patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470703 | PMC |
| http://dx.doi.org/10.3390/diagnostics11091577 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive Value of NT-proBNP, FGF21, Galectin-3 and Copeptin in Advanced Heart Failure in Patients with Preserved and Mildly Reduced Ejection Fraction and Type 2 Diabetes Mellitus.
Medicina (Kaunas)
November 2024
Department of Medical Biochemistry, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
: Heart failure (HF) is one of the most common initial presentations of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM). There are different cardiac biomarkers related to the pathophysiological mechanisms of HF in T2DM. The current research aims to identify additional biomarkers that could improve the diagnosis and prognosis of HFpEF, which is currently assessed using NT pro-BNP levels.
View Article and Find Full Text PDFExploring in vivo and in vitro models for heart failure with biomarker insights: a review.
Egypt Heart J
October 2024
Pharmacology Department, L. M. College of Pharmacy, Ahmedabad, Gujarat, 380009, India.
Background: Heart failure (HF) is a condition characterized by the heart's inability to meet the body's demands, resulting in various complications. Two primary types of HF exist, namely HF with preserved left ventricular ejection fraction (LVEF) and HF reduced with LVEF. The progression of HF involves compensatory mechanisms such as cardiac hypertrophy, fibrosis, and alterations in gene expression.
View Article and Find Full Text PDFChronic Kidney Disease Associated with Ischemic Heart Disease: To What Extent Do Biomarkers Help?
Life (Basel)
December 2023
Department of Internal Medicine, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
Article Synopsis
- Chronic kidney disease leads to reduced kidney function and is associated with complications like inflammation and electrolyte imbalances, which can increase cardiovascular risks.
- Cardiovascular issues, particularly ischemic heart problems, are a major cause of death in patients with chronic kidney disease, indicating a link between the two conditions.
- The study aims to explore this relationship by identifying specific biomarkers that could help with diagnosis and treatment, focusing on various proteins that indicate heart and kidney health.
Blood biomarkers for predicting coagulopathy occurrence in patients with traumatic brain injury: a systematic review.
Biomark Med
August 2022
Department of Neurosurgery, University Hospital of Ioannina, Ioannina, 45500, Greece.
The occurrence of coagulopathy in patients with traumatic brain injury (TBI) is related to severe complications. The authors performed the first systematic review to investigate whether biomarkers can predict the occurrence of hypocoagulopathy or progressive hemorrhagic injury in patients with TBI. The authors included studies that performed a receiver operating characteristics analysis for the biomarker and provided a clear value along with the respective sensitivity and specificity.
View Article and Find Full Text PDFBiomarkers Utility: At the Borderline between Cardiology and Neurology.
J Cardiovasc Dev Dis
October 2021
1st Medical Department, University of Medicine and Pharmacy "Grigore T. Popa", 700115 Iasi, Romania.
Biomarkers are important diagnostic and prognostic tools as they provide results in a short time while still being an inexpensive, reproducible and accessible method. Their well-known benefits have placed them at the forefront of research in recent years, with new and innovative discoveries being implemented. Cardiovascular and neurological diseases often share common risk factors and pathological pathways which may play an important role in the use and interpretation of biomarkers' values.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!